Skip to Content

Farhad Ravandi-Kashani, M.D.

Present Title & Affiliation

Primary Appointment

Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Chief, Section of Developmental Therapeutics, Texas University MD Anderson Cancer Center, Houston, TX

Bio Statement

I am a Professor and Chief, Section of Developmental Therapeutics within the Department of Leukemia, Division of Cancer Medicine at MD Anderson; I am actively involved in clinical and translational research for the treatment of patients with various hematological malignancies, in particular leukemias.  I have extensively published my clinical research results in the field of adult leukemias, with a focus on acute leukemias.

Education & Training

Degree-Granting Education

1988 St. Mary's Hospital Medical School/Imperial College, University of London, London, United Kingdom, MBBS, Medicine

Postgraduate Training

7/1999-7/2000 Fellow, Blood and Marrow Transplantation, Hematology/Stem Cell Transplantation, The University of Texas MD Anderson Cancer Center, Houston, TX, Dr. R. Champlin
7/1997-7/1999 Clinical Fellowship, Hematology/Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, Dr. R. Pazdur
7/1996-7/1997 Clinical Residency, Hematology, Baylor College of Medicine, Houston, TX, Dr. R. Lynch
6/1994-7/1996 Clinical Residency, Internal Medicine, The University of Texas - Houston, Houston, TX, Dr. V. Lavie
8/1989-8/1993 Senior House Officer/Registrar, Emergency Medicine, Internal Medicine, Hematology, University of London, London, United Kingdom

Board Certifications

1/2000 Hematology, Recertification Date: 11/2011
1/1996 American Board of Internal Medicine, Recertification Date: 10/2006
1/1999 Medical Oncology
1/1993 ECFMG
1/1993 FLEX


Academic Appointments

Associate Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 1/2003-8/2012
Assistant Professor, Stem Cell Transplant, Department of Hematology/Oncology, University of Illinois, College of Medicine, Chicago, IL, 2001-2003
Assistant Professor, Department of Hematology/Oncology, University of Illinois, College of Medicine, Chicago, IL, 9/2000-7/2003

Administrative Appointments/Responsibilities

Director, Leukemia/Hematologic Malignancies Program, The University of Illinois, Chicago, IL, 2000-2003

Other Appointments/Responsibilities

Member, Clinical Research Committee, Chicago, IL, 2001-2003

Institutional Committee Activities

Member, UT M. D. Anderson Clinical Research Committee II, 2005-present

Selected Publications

Peer-Reviewed Original Research Articles

1. Quintás-Cardama A, Cortes JE, O'Brien S, Ravandi F, Borthakur G, Liu D, Bleickardt E, Chen TT, Kantarjian HM. Dasatinib early intervention after cytogenetic or hematologic resistance to imatinib in patients with chronic myeloid leukemia. Cancer 115(13):2912-21, 7/2009. PMCID: PMCPMC4176768.
2. Garg R, Kantarjian H, Thomas D, Faderl S, Ravandi F, Lovshe D, Pierce S, O'Brien S. Adults with acute lymphoblastic leukemia and translocation (1;19) abnormality have a favorable outcome with hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with methotrexate and high-dose cytarabine chemotherapy. Cancer 115(10):2147-54, 5/2009. PMID: 19298009.
3. Fava C, Kantarjian HM, Jabbour E, O'Brien S, Jain N, Rios MB, Garcia-Manero G, Ravandi F, Verstovsek S, Borthakur G, Shan J, Cortes J. Failure to achieve a complete hematologic response at the time of a major cytogenetic response with second-generation tyrosine kinase inhibitors is associated with a poor prognosis among patients with chronic myeloid leukemia in accelerated or blast phase. Blood 113(21):5058-63, 5/2009. e-Pub 3/2009. PMCID: PMC4081366.
4. Vega-Ruiz A, Faderl S, Estrov Z, Pierce S, Cortes J, Kantarjian H, Ravandi F. Incidence of extramedullary disease in patients with acute promyelocytic leukemia: a single-institution experience. Int J Hematol 89(4). e-Pub 4/2009. PMID: 19340529.
5. Huh YO, Medeiros LJ, Ravandi F, Konoplev S, Jorgensen JL, Miranda RN. T-cell large granular lymphocyte leukemia associated with myelodysplastic syndrome: a clinicopathologic study of nine cases. Am J Clin Pathol 131(3):347-56, 3/2009. PMID: 19228641.
6. Garg R, Faderl S, Garcia-Manero G, Cortes J, Koller C, Huang X, York S, Pierce S, Brandt M, Beran M, Borthakur G, Kantarjian H, Ravandi F. Phase II study of rabbit anti-thymocyte globulin, cyclosporine and granulocyte colony-stimulating factor in patients with aplastic anemia and myelodysplastic syndrome. Leukemia 23(7). e-Pub 2/2009. PMID: 19242494.
7. Verstovsek S, Tefferi A, Kantarjian H, Manshouri T, Luthra R, Pardanani A, Quintas-Cardama A, Ravandi F, Ault P, Bueso-Ramos C, Cortes JE. Alemtuzumab therapy for hypereosinophilic syndrome and chronic eosinophilic leukemia. Clin Cancer Res 15(1):368-373, 2009. PMID: 19118067.
8. Ravandi F, Estey E, Jones D, Faderl S, O'Brien S, Fiorentino J, Pierce S, Blamble D, Estrov Z, Wierda W, Ferrajoli A, Verstovsek S, Garcia-Manero G, Cortes J, Kantarjian H. Effective treatment of acute promyelocytic leukemia with ALL-trans retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin. J Clin Oncol 27(4):504-510, 2009. e-Pub 12/2008. PMID: 19075265.
9. De Padua Silva L, de Lima M, Kantarjian H, Faderl S, Kebriaei P, Giralt S, Davisson J, Garcia-Manero G, Champlin R, Issa JP, Ravandi F. Feasibility of allo-SCT after hypomethylating therapy with decitabine for myelodysplastic syndrome. Bone Marrow Transplant 43(11). e-Pub 2009. PMID: 19151791.
10. Verma D, O'Brien S, Thomas D, Fadeerl S, Koller C, Pierce S, Kebriaei P, Garcia-Manero G, Cortes J, Kantarjian H, Ravandi F. Therapy-related acute myelogenous leukemia and myelodysplastic syndrome in patients with acute lymphoblastic leukemia treated with the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimens. Cancer 115(1):101-106, 2009. PMCID: PMC4180242.
11. Schimmer AD, O'Brien S, Kantarjian H, Brandwein J, Cheson BD, Minden MD, Yee K, Ravandi F, Giles F, Schuh A, Gupta V, Andreeff M, Koller C, Chang H, Kamel-Reid S, Berger M, Viallet J, Borthakur G. A phase I study of the pan bcl-2 family inhibitor obatoclax mesylate in patients with advanced hematologic malignancies. Clin Cancer Res 14(24):8295-8301, 12/2008. PMID: 19088047.
12. Jones D, Luthra R, Cortes J, Thomas D, O'Brien S, Bueso-Ramos C, Hai S, Ravandi F, de Lima M, Kantarjian H, Jorgensen JL. BCR-ABL fusion transcript types and levels and their interaction with secondary genetic changes in determining the phenotype of Philadelphia chromosome-positive leukemias. Blood 112(13):5190-5192, 12/2008. e-Pub 9/2008. PMCID: PMC2597614.
13. O'Brien S, Thomas D, Ravandi F, Faderl S, Cortes J, Borthakur G, Pierce S, Garcia-Manero G, Kantarjian HM. Outcome of adults with acute lymphocytic leukemia after second salvage therapy. Cancer 113(11):3186-3191, 12/2008. PMID: 18846563.
14. Mori S, Cortes J, Kantarjian H, Zhang W, Andreef M, Ravandi F. Potential role of sorafenib in the treatment of acute myeloid leukemia. Leuk Lymphoma 49(12):2246-2255, 12/2008. PMCID: PMC4086439.
15. Borthakur G, Kantarjian H, Wang X, Plunkett WK, Gandhi VV, Faderl S, Garcia-Manero G, Ravandi F, Pierce S, Estey EH. Treatment of core-binding-factor in acute myelogenous leukemia with fludarabine, cytarabine, and granulocyte colony-stimulating factor results in improved event-free survival. Cancer 113(11):3181-3185, 12/2008. PMCID: PMC4126078.
16. Yanada M, Borthakur G, Garcia-Manero G, Ravandi F, Faderl S, Pierce S, Kantarjian H, Estey E. Blood counts at time of complete remission provide additional independent prognostic information in acute myeloid leukemia. Leuk Res 32(10):1505-1509, 10/2008. e-Pub 4/2008. PMCID: PMCPMC4182927.
17. Faderl S, Ferrajoli A, Wierda W, Huang X, Verstovsek S, Ravandi F, Estrov Z, Borthakur G, Kwari M, Kantarjian HM. Clofarabine combinations as acute myeloid leukemia salvage therapy. Cancer 113(8):2090-2096, 10/2008. PMCID: PMC4163782.
18. O'Brien S, Thomas DA, Ravandi F, Faderl S, Pierce S, Kantarjian H. Results of the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen in elderly patients with acute lymphocytic leukemia. Cancer 113(8):2097-2101, 10/2008. PMID: 18720356.
19. Faderl S, Ravandi F, Huang X, Garcia-Manero G, Ferrajoli A, Estrov Z, Borthakur G, Verstovsek S, Thomas DA, Kwari M, Kantarjian HM. A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood 112(5):1638-45, 9/2008. e-Pub 6/2008. PMCID: PMC4081352.
20. Kantarjian H, O'Brien S, Ravandi F, Cortes J, Shan J, Bennett JM, List A, Fenaux P, Sanz G, Issa JP, Freireich EJ, Garcia-Manero G. Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System. Cancer 113(6):1351-1361, 9/2008. PMCID: PMCPMC4188533.
21. Vega-Ruiz A, O'Brien S, Cortes J, Kebriaei P, Thomas D, Kantarjian H, Ravandi F. Secondary myelodysplastic syndrome in a patient with Philadelphia-positive acute lymphoblastic leukemia after achieving a major molecular response with hyperCVAD plus imatinib mesylate. Leuk Res 32(9):1468-1471, 9/2008. e-Pub 3/2008. PMCID: PMC4086363.
22. Stock W, Undevia SD, Bivins C, Ravandi F, Odenike O, Faderl S, Rich E, Borthakur G, Godley L, Verstovsek S, Artz A, Wierda W, Larson RA, Zhang Y, Cortes J, Ratain MJ, Giles FJ. A phase I and pharmacokinetic study of XK469R (NSC 698215), a quinoxaline phenoxypropionic acid derivative, in patients with refractory acute leukemia. Invest New Drugs 26(4):331-338, 8/2008. e-Pub 4/2008. PMID: 18425419.
23. Tam CS, Kantarjian H, Garcia-Manero G, Borthakur G, O'Brien S, Ravandi F, Shan J, Cortes J. Failure to achieve a major cytogenetic response by twelve months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia. Blood 112(3):516-518, 8/2008. e-Pub 5/2008. PMCID: PMC4082324.
24. Yanada M, Borthakur G, Ravandi F, Bueso-Ramos C, Kantarjian H, Estey E. Kinetics of bone marrow blasts during induction and achievement of complete remission in acute myeloid leukemia. Haematologica 93(8):1263-1265, 8/2008. e-Pub 6/2008. PMID: 18519513.
25. Jabbour E, Kantarjian H, Jones D, Breeden M, Garcia-Manero G, O'Brien S, Ravandi F, Borthakur G, Cortes J. Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy. Blood 112(1):53-5, 7/2008. e-Pub 4/2008. PMCID: PMC4081375.
26. Borthakur G, Alvarado Y, Ravandi-Kashani F, Cortes J, Estrov Z, Faderl S, Ivy P, Bueso-Ramos C, Nebiyou Bekele B, Giles F. Phase 1 study of XL119, a rebeccamycin analog, in patients with refractory hematologic malignancies. Cancer 113(2):360-366, 7/2008. PMCID: PMC4126069.
27. Quintás-Cardama A, Tong W, Kantarjian H, Thomas D, Ravandi F, Kornblau S, Manshouri T, Cortes JE, Garcia-Manero G, Verstovsek S. A phase II study of 5-azacitidine for patients with primary and post-essential thrombocythemia/polycythemia vera myelofibrosis. Leukemia 22(5):965-70, 5/2008. e-Pub 4/2008. PMID: 18385750.
28. Borthakur G, Ahdab SE, Ravandi F, Faderl S, Ferrajoli A, Newman B, Issa JP, Kantarjian H. Activity of decitabine in patients with myelodysplastic syndrome previously treated with azacitidine. Leuk Lymphoma 49(4):690-695, 4/2008. PMCID: PMC3702160.
29. Yanada M, Garcia-Manero G, Borthakur G, Ravandi F, Kantarjian H, Estey E. Relapse and death during first remission in acute myeloid leukemia. Haematologica 93(4):633-634, 4/2008. PMID: 18379012.
30. Garcia-Manero G, Shan J, Faderl S, Cortes J, Ravandi F, Borthakur G, Wierda WG, Pierce S, Estey E, Liu J, Huang X, Kantarjian H. A prognostic score for patients with lower risk myelodysplastic syndrome. Leukemia 22(3):538 - 543, 3/2008. e-Pub 12/2007. PMID: 18079733.
31. Kantarjian H, O'Brien S, Shan J, Huang X, Garcia-Manero G, Faderl S, Ravandi-Kashani F, Verstovsek S, Beth Rios M, Cortes J. Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia - need for new response definitions? Cancer 112(4):837-845, 2/2008. PMID: 18085610.
32. O'Brien S, Ravandi F, Riehl T, Wierda W, Huang X, Tarrand J, O'Neal B, Kantarjian H, Keating M.. Valganciclovir prevents cytomegalovirus reactivation in patients receiving alemtuzumab-based therapy. Blood 111(4):1816-1819, 2/2008. e-Pub 11/2007. PMID: 18039954.
33. Tsimberidou AM, Wierda WG, Plunkett W, Kurzrock R, O'Brien S, Wen S, Ferrajoli A, Ravandi-Kashani F, Garcia-Manero G, Estrov Z, Kipps TJ, Brown JR, Fiorentino A, Lerner S, Kantarjian HM, Keating MJ. Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol 26(2):196-203, 1/10/2008. PMID: 18182662.
34. Herling M, Patel KA, Teitell MA, Konopleva M, Ravandi F, Kobayashi R, Jones D. High TCL1 expression and intact T-cell receptor signaling define a hyperproliferative subset of T-cell prolymphocytic leukemia. Blood 111(1):328-337, 1/2008. e-Pub 9/2007. PMCID: PMC2200815.
35. Ma W, Zhang X, Jilani I, Ravandi F, Estey E, Kantarjian H, Giles F, Sheikholeslami M, Keating M, Albitar M. Detection of nucleophosmin gene mutations in plasma from patients with acute myeloid leukemia: clinical significance and implications. Cancer Biomark 110 (supp 1):840a, 2007. PMID: 19242062.


1. Ravandi F. Therapy-related acute promyelocytic leukemia: further insights into the molecular basis of the disease and showing the way forward in therapy. Leuk Lymphoma 50(7):1073-4, 7/2009. PMCID: PMC4109290.


1. Faderl S, Wetzler M, Rizzieri D, Schiller GH, Jagasia MH, Stuart RK, Ganguly S, Avigan D, Craig M, Collins R, Maris MB, Kovacsovics T, Goldberg S, Seiter K, Hari P, Ravandi F, Wang ES, Eckert S, Huebner D, Kantarjian H. Clofarabine plus cytarabine compared to cytarabine alone in older patients with relapsed or refractory (R/R) acute myelogenous leukemia (AML): Results from the phase III CLASSIC 1 trial. J Clin Oncol 29(15_suppl):6503, 6/2011.

Grant & Contract Support

Title: 2010-0692: A Phase 3, Randomized, Controlled Double-Blind, Multinational Clinical Study of the Efficacy and Safety of Vosaroxin and Cytarabine Versus Placebo and Cytarabine in Patients with First Relapsed or Refractory Acute Myeloid Leukemia (VALOR)
Funding Source: Sunesis
Role: Principal Investigator
Duration: 11/2/2010 - 9/10/2015

Last updated: 8/12/2015